The Japanese pharmaceutical company Taiho Pharmaceutical is set to acquire the Swiss antibody-drug conjugate (ADC) company Araris Biotech for $400 million. Taiho and Araris have been collaborating to ...
Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the ...
The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is ...
Pharmaceutical Technology on MSN4d
Taiho outlays $1.14bn to acquire ADC specialist ArarisTaiho Pharmaceutical has agreed to acquire Swiss-based antibody-drug-conjugate (ADC) specialist Araris Biotech for up to ...
Taiho Pharmaceutical Co., Ltd.Araris Biotech AGTaiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris ...
By Daniella Parra Taiho Pharmaceutical said it will acquire Araris Biotech, a leader in antibody drug conjugates (ADCs), for an initial $400 million, with potential additional milestone payments of up ...
Press Release4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 ...
The antibody-drug conjugate (ADC) juggernaut powers on, with Japan’s Taiho Pharmaceutical Co. set to acquire Araris Biotech ...
Taiho Pharma to buy next-generation ADC drug discovery company ,Araris Biotech: Japan Tuesday, March 18, 2025, 16:00 Hrs [IST] Taiho Pharmaceutical Co., Ltd., an R&D-driven specia ...
By acquiring Araris' innovative ADC drug discovery technology platform along with Cysteinomix, Taiho Pharmaceutical will further expand its ongoing development portfolio in the field of oncology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback